EURECCA (European Registration of Cancer Care):
an ESSO initiative
|Introduction||Relevant Background||Strategic plan|
|Newsletters||Consensus Conference||Tumour Site Groups||Structure|
EURECCA (acronym for EUropean REgistry of Cancer CAre or EURopEan CanCer Audit), started in 2007 as an ECCO/ESSO initiative. EURECCA is an international multidisciplinary platform of clinicians and epidemiologists aiming to improve the quality of cancer care by data registration, feedback, forming plans for improvement and sharing knowledge of performance and science. EURECCA is registered as a foundation, based in Leiden.
Relevant background: Still considerable variation exists in Europe in cancer management and outcome. Moreover, there is an urgent need for transparent uniform international data collection and analysis, in order to monitor and learn from all aspects of cancer care and to provide feedback and education. Uniform datasets are necessary, not existent yet.
The strategic plan of EURECCA was written in 2013 to professionalize EURECCA in the next 6 years (2014-2020).
The vision - EURECCA will become the trademark for quality assurance in cancer management in Europe, and provide a dedicated infrastructure to audit patient outcome, monitor standardized cancer care and assure equal access for cancer patients to high quality care in all European countries. Synergy with the epidemiological network to collaboratively reach common goals is actively pursued to form one front. Web based dashboard with highly secured information on performance and enhancement proposals are future perspectives.
The mission of EURECCA is achieving and assuring high quality of multidisciplinary cancer management in Europe, accessible to all patients through the development and support of an international quality assurance structure, which is an audit structure, using anonymous patient data and compliant with national and international laws.
EURECCA’s goal is toenlarge the European platform and infrastructure to cooperate with national registries or audit structures, expand the coverage of cancer patient outcome data that is captured and audit the quality of multidisciplinary cancer care. Registration of outcome-based quality measurements will provide internal feed-back, benchmarking as well as transparency which will rapidly lead to improvements in cancer care.
EURECCA’s Key activities in the next six year will focus on
1. building a professional support structure
2. increase EURECCA network and optimize ICT structure for data collection and processing, auditing
3. development of cancer treatment guidelines, education and communication
4. fundraising and income generation.
Source: Six years plan to professionalize EURECCA, for more information please see the Strategic plan.
EURECCA has an internationally recognized set of expertise to augment Quality assurance in cancer care and access to expertise’s, and a large network all of value to stakeholders such as Physicians, Scientific societies, Patient organizations, Policy makers and Pharma:
- Data collection, large database mining, study facilitation and processing of data. Analysis with SPSS, STATA, SAS, excel etc. Epidemiologists and statisticians who are specialized in this field of merging different data bases.
- Defining uniform datasets.
- Reporting to all contacts from Cancer registries and/or national or regional audits. Writing manuscripts in collaborating with participants on the results of the analysis.
- Organizing international consensus conferences, symposia and meeting with the Board per tumour site group.
- Education (development of E-learning multidisciplinary educational program/workshops), assisting in guideline formation and writing patient friendly summaries. Active patient involvement in improvement of cancer care.
- Support multidisciplinary cancer care, integrated care pathways.
- Organize international collaboration in pioneering treatments to improve cancer care and outcome analysis (Such as non-surgical Wait&Watch after upfront CRT)
Activity report 2016
The Role of resection of thr primary tumour for asymptomatic incurable mestastatic colorectal cancer
Adjuvant chemotherapy and relative survival of patients with stage II colon cancer
Treatment strategies and relative survival of patients with stage I-III rectal cancer
Hormone receptor-postive locally advanced or metastatic breast cancer who have received no prior endocrine therapy
INSPIRE - International Nipple Sparing Mastectomy Registry
International Watch and Wait database (IWWD)
EURECCA Newsletter - Jan 2015
EURECCA Newsletter - October 2015
EURECCA Newsletter - April 2016
EURECCA CONSENSUS CONFERENCE
To achieve this ambitious aim a first consensus conference on colon and rectal cancer was organised in December 2012. Consensus meetings are held to standardise good clinical practice in cancer care. This event brought together an expert panel of health care professionals and scientists representing the majority of European scientific organizations involved in colon and rectal cancer care (surgeons, medical oncologists, radiologists, pathologists, radiation oncologists, and nurses) together with patient organisation representatives. The panel was invited to comment on 465 evidence-based statements of cancer care. This process is described in the article entitiled : “Involving patients in a multidisciplinary European consensus process and in the development of a ‘Patient Summary of the Consensus Document for colon and rectal cancer care’.”
Summary on the Consensus on colon & Rectal Cancer Care (October 2013)
Questionnaire: Value of the Summary of the Consensus Conference on Colon & Rectal Cancer
1) Beets GL, Figueiredo NL, Habr-Gama A, van de Velde CJ. A new paradigm for rectal cancer: Organ preservation: Introducing the International Watch & Wait Database (IWWD). Eur J Surg Oncol. 2015 Oct 19. pii: S0748-7983(15)00774-X. doi: 10.1016/j.ejso.2015.09.008. [Epub ahead of print] PubMed PMID: 26493223.
2) Messager M, de Steur WO, van Sandick JW, Reynolds J, Pera M, Mariette C, Hardwick RH, Bastiaannet E, Boelens PG, van deVelde CJ, Allum WH; EURECCA Upper GI Group. Variations among 5 European countries for curative treatment of resectable oesophageal and gastric cancer: A survey from the EURECCA Upper GI Group (EUropean REgistration of Cancer CAre). Eur J Surg Oncol. 2015 Sep 30. pii: S0748-7983(15)00792-1. doi: 10.1016/j.ejso.2015.09.017. [Epub ahead of print] PubMed PMID: 26461256.
3) Kiderlen M, Ponti A, Tomatis M, Boelens PG, Bastiaannet E, Wilson R, van de Velde CJ, Audisio RA; eusomaDB Working Group. Variations in compliance to quality indicators by age for 41,871 breast cancer patients across Europe: a European Society of Breast Cancer Specialists database analysis. Eur J Cancer. 2015 Jul;51(10):1221-30. doi: 10.1016/j.ejca.2015.03.013. Epub 2015 Apr 16. PubMed PMID: 25892645.
4) Kiderlen M, Walsh PM, Bastiaannet E, Kelly MB, Audisio RA, Boelens PG, Brown C, Dekkers OM, de Craen AJ, van de Velde CJ, Liefers GJ. Treatment strategies and survival of older breast cancer patients - an international comparison between the Netherlands and Ireland. PLoS One. 2015 Feb 3;10(2):e0118074. doi: 10.1371/journal.pone.0118074. eCollection 2015. PubMed PMID: 25646756; PubMed Central PMCID: PMC4315587.
5) van den Broek CB, van Gijn W, Bastiaannet E, Møller B, Johansson R, Elferink MA, Wibe A, Påhlman L, Iversen LH, Penninckx F, Valentini V, van de Velde CJ; EURECCA Consortium. Differences in pre-operative treatment for rectal cancer between Norway, Sweden, Denmark, Belgium and the Netherlands. Eur J Surg Oncol. 2014 Dec;40(12):1789-96. doi: 10.1016/j.ejso.2014.09.011. Epub 2014 Oct 18. PubMed PMID: 25454831.
6) Quality assurance in surgical oncology the EURECCA platform. Eur J Surg Oncol. 2014 Nov;40(11):1387-90. doi: 10.1016/j.ejso.2014.08.478. Epub 2014 Aug 29. PubMed PMID: 25256785.
7 ) Boelens PG, Taylor C, Henning G, Marang-van de Mheen PJ, Espin E, Wiggers T, Gore-Booth J, Moss B, Valentini V, van de Velde CJ. Involving patients in a multidisciplinary European consensus process and in the development of a 'patient summary of the consensus document for colon and rectal cancer care'. Patient. 2014;7(3):261-70. doi: 10.1007/s40271-014-0061-4. PubMed PMID: 24862378.
8) Breugom AJ, Boelens PG, van den Broek CB, Cervantes A, Van Cutsem E, Schmoll HJ, Valentini V, van de Velde CJ. Quality assurance in the treatment of colorectal cancer: the EURECCA initiative. Ann Oncol. 2014 Aug;25(8):1485-92. doi: 10.1093/annonc/mdu039. Epub 2014 Mar 26. Review. PubMed PMID: 24671742.
9 ) Tudyka V, Blomqvist L, Beets-Tan RG, Boelens PG, Valentini V, van de Velde CJ, Dieguez A, Brown G. EURECCA consensus conference highlights about colon & rectal cancer multidisciplinary management: the radiology experts review. Eur J Surg Oncol. 2014 Apr;40(4):469-75. doi: 10.1016/j.ejso.2013.10.029. Epub 2013 Dec 14. Review. PubMed PMID: 24439446.
10) Valentini V, Glimelius B, Haustermans K, Marijnen CA, Rödel C, Gambacorta MA, Boelens PG, Aristei C, van de Velde CJ. EURECCA consensus conference highlights about rectal cancer clinical management: the radiation oncologist's expert review. Radiother Oncol. 2014 Jan;110(1):195-8. doi:
10.1016/j.radonc.2013.10.024. Epub 2013 Nov 25. Review. PubMed PMID: 24286634.
11) van de Velde CJ, Boelens PG, Tanis PJ, Espin E, Mroczkowski P, Naredi P, Pahlman L, Ortiz H, Rutten HJ, Breugom AJ, Smith JJ, Wibe A, Wiggers T, Valentini V. Experts reviews of the multidisciplinary consensus conference colon and rectal cancer 2012: science, opinions and experiences from the experts of surgery. Eur J Surg Oncol. 2014 Apr;40(4):454-68. doi: 10.1016/j.ejso.2013.10.013. Epub 2013 Nov 8. Review. PubMed PMID: 24268926.
12) Quirke P, West NP, Nagtegaal ID. EURECCA consensus conference highlights about colorectal cancer clinical management: the pathologists expert review. Virchows Arch. 2014 Feb;464(2):129-34. doi: 10.1007/s00428-013-1534-x. Epub 2014 Jan 24. Review. PubMed PMID: 24458515.
13) van de Velde CJ, Boelens PG, Borras JM, Coebergh JW, Cervantes A, Blomqvist L, Beets-Tan RG, van den Broek CB, Brown G, Van Cutsem E, Espin E, Haustermans K, Glimelius B, Iversen LH, van Krieken JH, Marijnen CA, Henning G, Gore-Booth J, Meldolesi E, Mroczkowski P, Nagtegaal I, Naredi P, Ortiz H, Påhlman L, Quirke P, Rödel C, Roth A, Rutten H, Schmoll HJ, Smith JJ, Tanis PJ, Taylor C, Wibe A, Wiggers T, Gambacorta MA, Aristei C, Valentini V. EURECCA colorectal: multidisciplinary management: European consensus conference colon & rectum. Eur J Cancer. 2014 Jan;50(1):1.e1-1.e34. doi: 10.1016/j.ejca.2013.06.048. Epub 2013 Oct 31. PubMed PMID: 24183379.
14) Lordick F, Allum W, Carneiro F, Mitry E, Tabernero J, Tan P, Van Cutsem E, van de Velde C, Cervantes A. Unmet needs and challenges in gastric cancer: the way forward. Cancer Treat Rev. 2014 Jul;40(6):692-700. doi: 10.1016/j.ctrv.2014.03.002. Epub 2014 Mar 13. Review. PubMed PMID: 24656602.
15) van de Velde CJ, Aristei C, Boelens PG, Beets-Tan RG, Blomqvist L, Borras JM, van den Broek CB, Brown G, Coebergh JW, Cutsem EV, Espin E, Gore-Booth J, Glimelius B, Haustermans K, Henning G, Iversen LH, Han van Krieken J, Marijnen CA, Mroczkowski P, Nagtegaal I, Naredi P, Ortiz H, Påhlman L, Quirke P, Rödel C, Roth A, Rutten HJ, Schmoll HJ, Smith J, Tanis PJ, Taylor C, Wibe A, Gambacorta MA, Meldolesi E, Wiggers T, Cervantes A, Valentini V; European Registration of Cancer Care. EURECCA colorectal: multidisciplinary mission statement on better care for patients with colon and rectal cancer in Europe. Eur J Cancer. 2013 Sep;49(13):2784-90. doi: 10.1016/j.ejca.2013.04.032. Epub 2013 Jun 14. PubMed PMID: 23769991.
16) de Steur WO, Henneman D, Allum WH, Dikken JL, van Sandick JW, Reynolds J, Mariette C, Jensen L, Johansson J, Kolodziejczyk P, Hardwick RH, van de Velde CJ; EURECCA Upper GI Group. Common data items in seven European oesophagogastric cancer surgery registries: towards a European upper GI cancer audit (EURECCA Upper GI). Eur J Surg Oncol. 2014 Mar;40(3):325-9. doi: 10.1016/j.ejso.2013.11.021. Epub 2013 Dec 13. PubMed PMID: 24412054.
- EURECCA ColoRectal Cancer, anno 2007
- EURECCA Upper GI cancer, anno 2009
- EURECCA Breast Cancer, anno 2012
- EURECCA Hepato-pancreatico-bilairy cancer, 2012
- EURECCA Prostate Cancer, anno 2013
- EURECCA Lung Cancer to be started 2014
FUTURE PROJECTS & ETHICS
Expand to other countries per tumour site group, and other tumour sites and invite them to participate multidisciplinary in turn of support and feedback on a regular basis. With the ethical promises that data will be anonymously be processed and reported, only predefined and approved analysis will be done. Withdrawal of data is possible at any moment in time.
EURECCA Structure and interactions with relevant stakeholders
EURECCA prefers a parallel independent infrastructure supporting tumour site group and national and regional cancer registries and audits. A pure synergy with the Epidemiology network. EURECCA will closely collaborate and deliver service and knowledge to the Blue organization by means of quality assurance projects, education, communication and support in guideline formation.
EURECCA is supported by ESSO and by ECCO-the European Cancer Organisation.
Please see the website of ECCO HTTP://WWW.ECCO-ORG.EU/
Martine Piccart, President of ECCO, talks about her vision for ECCO.